| Factor Information | |
|---|---|
| Data ID | 1846 |
| Factor | New York heart functional classification |
| Description | The New York heart functional classification was improved significantly after a 2, 4, and 6-month therapy [(2.0±0.5, 1.8±0.4, and 1.7±0.5, respectively; P<0.001 vs pre-medication score (2.9±0.5)). |
| Biomarker | NA |
| Classification | A3 (clinical factor - disease & symptom) |
| Association | |
|---|---|
| Application | Treatment |
| Objective | The New York heart functional classification was improved significantly after a 2, 4, and 6-month therapy |
| p Value | <0.001 |
| Conclusion | Oral bosentan can effectively relieve the symptoms, decrease PA hypertension, and improve exercise tolerance and cardiac function classification in patients with PA hypertension associated with congenital heart disease with good safety and mild side effects. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 554 |
| CHD Type | isolated CHD/non-isolated CHD |
| CHD Subtype | VSD/VSD, PDA/AS/PDA/VSD, PDA/DORV, VSD/AVSD/ES |
| Reference | |
|---|---|
| PMID | 25537917 |
| Year | 2015 |
| Title | Efficacy of oral bosentan for treatment of congenital heart disease-associated pulmonary arterial hypertension |
| Sample | ||
|---|---|---|
| Population | All | |
| Source | N/A | |
| Region | Beijing, China | |
| Method | Liver and kidney function, again measured 6MWD, color echocardiography of the heart, and evaluated cardiac function grading, and measured oxygen saturation | |
| Race | Asian | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | after 4 month therapy(Treatment) | pre-medication(Control) |
| Number | 24 | N/A |
| Age | 23.8±17.6 (5~57) years | 23.8±17.6 (5~57) years |
| Gender (Male: Female) | 8:16 | N/A |
| Marker Level | New York heart functional classification: 1.7±0.5 | New York heart functional classification: 2.9±0.5 |
